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Adipokines and ghrelin play role in insulin resistance, the key pathophysiological abnormality in patients with nonalcoholic fatty
liver diseases. In the present study, relationship between nonalcoholic steatohepatitis (NASH) and serum adipokine and ghrelin
levels was investigated. Thirty seven patients with biopsy-proven NASH and 25 age- and sex-matched controls were enrolled. Ten
of NASH patients (27%) had diabetes mellitus (n = 5) or impaired glucose tolerance (n = 5). Body mass index (BMI) was less
than 30kg/m2 in 67.6% of patients, while in the remaining 32.4% it was more than 30 kg/m2. Serum adiponectin, leptin, TNF-
α, and ghrelin were determined. Serum leptin (15.49 ± 4.84 vs 10.31 ± 2.53) and TNF-α (12.1 ± 2.7v s1 0 .31 ± 2.56) levels were
signiﬁcantlyhigherintheNASHgroupcomparedtointhecontrolgroup(P<. 001foreach).Nevertheless,adiponectin(11.1±2.1
vs17.3±2.8)andghrelin(6.46±1.1vs7.8±1.1)levelswerelowerintheNASHgroupthaninthecontrolgroup(P<. 001foreach).
Serum levels of the adipokines and ghrelin, however, were comparable in the subgroups of patients regardless of whether BMI was
< 30 or > 30 or glucose tolerance was impaired or not (P>. 05). Additionally, neither adipokines nor ghrelin was correlated with
histopathological grade and stage (P>. 05). In conclusion; there is a signiﬁcant relationship between NASH and adipokines and
ghrelin independent from BMI and status of the glucose metabolism. These cytokines that appear to have role in the pathogenesis
of NASH, however, do not have any eﬀect upon the severity of the histopathology.
Copyright © 2006 Mehmet Yalniz et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
It has been well established that nonalcoholic fatty liver
(NAFLD) is intimately related to various clinical and bio-
logical markers of the insulin resistance syndrome [1]. Fur-
thermore, there is a near-universal association between non-
alcoholic steatohepatitis (NASH), the severe and progressive
form of NAFLD, and insulin resistance, irrespective of obe-
sity [2].
Adipose tissue has currently been regarded as an ac-
tive player in the regulation of metabolism since the
discovery of several adipocyte-derived factors, collectively
known as adipokines [3]. In this context, numerous sub-
stances, mainly released by adipose tissue including tu-
mor necrosis factor-alpha (TNF-α), leptin, and adiponectin,
are closely linked to each other and are thought to con-
tribute to peripheral insulin resistance [4–7]. In addition,
ghrelin, a novel peptide isolated from human and rat
stomach, is also associated with insulin resistance beside
its role in glucose and energy hemostasis and food intake
[8].
Adipokines and ghrelin have been implicated in the
pathogenesis of NAFLD through their metabolic and/or
pro-/anti-inﬂammatory activity [9–12]. Despite the emerg-
ing data showing an association between NASH and the
aforementionedsubstances,existingresults,however,arestill
controversial. One reason for this discrepancy among the
studies is the disparity of the methods used in the studies
as well as the inhomogeneous feature of the study popula-
tions. Secondly, these parameters are determined separately
in most of the studies. Only in two recent studies [13, 14],
adiponectin, TNF-α, and leptin were collectively analyzed
in the same study population. These two studies, however,
have also yielded conﬂicting results. The only consistent re-
sult of the two studies was the association between hypoad-
iponectinemia and NASH.2 Mediators of Inﬂammation
In the present study, serum adipocytokines and, ad-
ditionally, ghrelin levels were determined in patients with
biopsy-proven NASH.
METHODS
Thirty seven patients with histopathologically proven NASH
and age- and sex- matched twenty ﬁve healthy individuals
were enrolled to the study.
Informed consent was obtained from each patient and
the study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki as reﬂected in a priori approval
by the institution’s human research committee. Local ethic
committee approved the study.
Control group consisted in individuals who had normal
abdominal ultrasound liver scans, normal transaminase val-
ues, normal fasting serum glucose levels, and normal glucose
tolerance tests.
The diagnosis of NASH was based on the following cri-
teria: (1) the presence of steatosis (> 10%), lobular inﬂam-
mation, and ballooning degeneration (with or withoutﬁbro-
sis) on liver biopsy; (2) the intake of less than 20g of ethanol
per day, as conﬁrmed by the physician and family members
who were in close contact with the patient; and (3) appro-
priate exclusion of other liver diseases such as alcoholic liver
disease, viral hepatitis, autoimmune hepatitis, drug-induced
liver disease, primary biliary cirrhosis, primary sclerosing
cholangitis, biliary obstruction, celiac disease, and metabolic
liver diseases. No patient had a history of jejunoileal bypass.
Histopathological grading and staging of the NASH was
madeaccordingtoBrunt’scriteria [15]byaspecialistpathol-
ogist, who also made the histopathological diagnosis of the
NASH.
Grading
Grading was made according to macrovesicular steatosis and
necroinﬂammatory activity.
Macrovesicular steatosis. Grade 0: no steatosis; Grade 1:
steatosis up to 33%; Grade 2: steatosis between 33 and 66%;
Grade 3: steatosis over 66%.
Necroinﬂammatory activity. Grade 1: mild; Grade 2:
moderate; Grade 3: severe.
Staging
Staging was made according to ﬁbrosis.
Stage 1: zone 3 perisinusoidal/pericellular ﬁbrosis; focal
or diﬀuse. Stage 2: focal or diﬀu s ep e r i p o r t a lﬁ b r o s i st o -
gether with zone 3 perisinusoidal/pericellular ﬁbrosis. Stage
3: focal and diﬀuse bridging necrosis together with perisinu-
soidal/pericellularﬁbrosisandportalﬁbrosis.Stage4:cirrho-
sis.
LaboratoryAnalyses
Blood samples were collected from patients and control
group after an overnight fasting. Aspartate and alanine ami-
notransferases (AST, ALT), total protein, albumin, alka-
line phosphatase, γ-glutamyl transpeptidase, HbsAg, an-
tiHCV, smooth muscle antibody, antimitochondrial anti-
body, serum cholesterol, triglyceride, fasting glucose levels,
insulin, C-peptide, and complete blood count were stud-
ied.
Patients with fasting serum glucose levels of more than
126mg/dL in at least two separate samples were identiﬁed
as having diabetes mellitus, and a ﬁnding of 140–200mg/dL
twohoursafterthestandardoralglucoseloadingwasconsid-
ered abnormal glucose tolerance test.
Homeostasis(HOMA)modelwasusedforestimatingthe
insulin resistance (IR).
HOMAIR(%) =fastingbloodglucose(mg/dL)/
18 ×fastinginsulin(μU/mL)/22.5.
As a measure of overweightness and/or obesity, body mass
index (BMI) was calculated as the weight (kg) divided by the
squareofheight(m2)inallparticipantsandthepatientswith
BMI of more than 30 were considered to show manifest obe-
sity according to the World Health Organization classiﬁca-
tion [16].
Analysesofserumadipokinesandghrelin
Serum samples were taken from the patients and healthy in-
dividuals after an overnight fasting and kept in −30◦Cu n -
til analyzed. TNF-α, leptin, adiponectin, and ghrelin levels
were analyzed with ELISA kits (TNF-α kit (range of detec-
tion: 0.5–32pg/mL, sensitivity: <= 0.09pg/mL) was pur-
chased from BioSource International Inc, 542, Flynn Road,
Camarillo, Calif, USA; ghrelin kit (range of detection: 0–
100ng/mL, sensitivity: 0.08ng/mL) from Phoenix Interna-
tional; adiponectin kit (range of detection: 0.23–15ng/mL,
sensitivity: 0.1ng/mL) from Chemicon International, Inc,
USA; and leptin kit (sensitivity: 0.2ng/mL)fromDRGIn-
ternational, Inc, USA).
Levels of adipokines and ghrelin are closely related to
bodyfatmassandmaysimplyreﬂecttheassociationbetween
NAFLD and other risk factors for liver diseases like obesity
and diabetes rather than a true causal relationship. Hence,
patients are divided into subgroups according to the BMI
and glucose metabolism status, in order to determine the
adipokines and ghrelin in study populations with diﬀerent
BMI and glucose metabolism that might have impact upon
the levels of these parameters.
Statisticalanalysis
All analyses were performed using the Statistical Package
for the Social Sciences (SPSS) for Windows, version 11,0
packed program. Data were presented as mean ± standard
deviation unless noted as diﬀerent. Diﬀerence between the
groups was analyzed using Mann-Whitney U test. The rela-
tionshipsamongthevariableswereanalyzedusingSpearman
correlation test. P<0.05 was considered statistically signiﬁ-
cant.Mehmet Yalniz et al 3
Table 1: Demographic and clinical data in control and NASH
groups.
Parameter Control NASH P
(n = 25) (n = 37)
Age (years) 37.1 ± 7.75 40.1 ±8.1 >. 05
Male/female (n) 10/15 25/12 >. 05
AST (IU/L) 19.6 ± 6.26 0 .6 ±34.6 <. 001
ALT (IU/L) 19.4 ± 4.5 114.9 ±87.9 <. 001
Glucose (mg/dL) 88.1 ± 24.7 113 ±44.9 <. 05
Cholesterol (mg/dL) 181.0 ± 33.1 202.7 ±41 >. 05
Triglyceride (mg/dL) 119.7 ± 65.8 225.7 ±112 <. 001
Impaired GT∗/DM (n) 0/05 /5 <. 001
BMI (kg/m2) 24.1 ± 1.92 8 .7 ±3.3 <. 05
HOMA index 1.75 ± 0.67 7.0 ±9.2 <. 001
∗GT: glucose tolerance.
RESULTS
Demographicandclinicaldataofthepatientsandthecontrol
subjects are shown in Table 1. Mean age and gender between
the control and NASH groups were comparable (P>0.05).
On the other hand, mean BMI and HOMA IR were signiﬁ-
cantly higher in the NASH group than in the control group
(P<0.05 and 0.001, resp). Control subjects had neither im-
paired glucose tolerance nor diabetes mellitus. Nonetheless,
ten (27.03%) of the thirty seven NASH patients had abnor-
malglucosemetabolism,ﬁvehadimpairedglucosetolerance,
and ﬁve had diabetes mellitus.
In histopathological analysis, nine (24.3%) of the 37 pa-
tients with NASH had grade 1, nineteen (51.4%) had grade
2, and nine (24.3%) had grade 3 disease. Most of the patients
(n = 23 (62.2%)) were in stage 2 histopathologically. The
distribution of the remaining patients was as follows: seven
(18.9%) in stage 0, one (2.7%) in stage 1, and six (16.2%) in
stage 3 disease.
Serumadipokineandghrelinlevels
Serum leptin and TNF-α levels were signiﬁcantly higher in
the NASH group compared to in the control group (P<
0.001 for each). Nevertheless, adiponectin and ghrelin levels
were found decreased in the NASH group than in the control
group (P<0.001 for each). These diﬀerences, however, were
not gender speciﬁc in the NASH group (P>0.05). Serum
levels of the adipokines and ghrelin were comparable in the
subgroups of patients regardless to whether BMI was < 30 or
> 30 or glucose tolerance was impaired or not (P>0.05).
Thevaluesoftheanalyzedsubstanceswerealsoexamined
in diﬀerent histopathological grade and stage of the NASH.
Nevertheless, serum adipokine and ghrelin levels were not
signiﬁcantly diﬀerent among the diﬀerent grades or stages
of the NASH (data not shown). On the other hand, patients
with higher stages of NASH had higher HOMA IR values
than patients with lower disease stages (P<0.05).
Serum adipokine and ghrelin levels in the control group
and patients with NASH and in patients with NASH are
shown in Table 2.
Relationshipbetweenthedeterminedparameters
andthehistopathologicalﬁndings
A signiﬁcant positive correlation was found only between
ghrelin and TNF-α (r = 0.491, P<0.05). Leptin had a
positive correlation with BMI (r = 0.335, P<0.05) and a
negative correlation with AST/ALT rate (r =− 0.328, P<
0.05). Neither adipokines nor ghrelin, however, correlated
with histopathological grade and stage (P>0.05).
DISCUSSION
The studies that evaluated serum adipokines separately
yielded conﬂicting results although an association with
NAFLD including NASH has been implicated. The results
of two recent comprehensive studies [13, 14] that examined
the adipokines (adiponectin, TNF-α, and leptin) in patients
with NASH are also at variance. The only consistent con-
sequence of both studies was the association between hy-
poadiponectinemia and NASH, which is also in line with the
present study. In addition, we found either TNF-α or lep-
tin remarkably increased in patients with NASH. In light of
these studies, it can be concluded that hypoadiponectinemia
and the levels of other adipokines in NASH appear to be a
part of a metabolic disturbance characterized by ectopic fat
accumulation in the central compartment. The discrepancy
among the results of these studies, however, appears to be
related to the diﬀerent nature of study populations; in par-
ticular, the study of Musso et al [14] which was consisted of
nondiabetic and nonobese NAFLD patients and virtually of
male gender (92%).
In addition to adipokines, we examined serum ghrelin
levels, too. This is the second study that examined ghre-
lin, a peptide intimately associated with insulin resistance;
in patients with NASH. In keeping with the previous study
[12], we found that serum ghrelin decreased in patients
with NASH irrespective of BMI and the status of the glu-
cose metabolism, the same as the adipokines. The obser-
vation that ghrelin levels are markedly reduced in patients
with NASH might reﬂect a possible hepato-protective role of
ghrelin similar to the adiponectin. If so, ghrelin-based future
therapeutic trials of NAFLD might be appealing.
Serum levels of adipokines are related to body fat mass
and diabetes. Hence, the presence of these confounding fac-
tors might hinder the interpretation of the association be-
tween adipokines and NAFLD. In this context, one of the re-
markable ﬁndings of the present study is the values of the
determined adipokines and ghrelin in patients with NASH
were signiﬁcantly diﬀerent from the control group not only
in patients with overt obesity (BMI > 30), impaired glucose
tolerance,orovertdiabetes,butalsoinpatientswithBMIless
than 30 or without impaired glucose tolerance or diabetes.
Moreover, although all of the examined substances are
closely related with insulin resistance, neither adipokines nor4 Mediators of Inﬂammation
Table 2: Data of the serum TNF-α, leptin, adiponectin, and ghrelin values in control and NASH groups and in diﬀerent subgroups of the
NASH patients.
Groups TNF-α (pg/mL) Leptin (ng/mL) Adiponectin (ng/mL) Ghrelin (ng/mL)
Control group (n = 25) 3.35 ±1.2∗ 10.3 ±2.53∗ 17.3 ±2.8∗ 7.8 ± 1.1∗
NASH group (n = 37) 12.1 ±2.7∗ 15.49 ±4.84∗ 11.1 ±2.1∗ 6.46 ± 1.1∗
Male (n = 25) 11.9 ±2.81 5 .3 ±5.21 1 ±2.36 .4 ±1.1
Female (n = 12) 12.3 ±2.51 5 .9 ±4.31 1 .3 ±1.96 .7 ±1.1
BMI < 30 (n = 25) 12.1 ±2.81 5 .1 ±5.01 1 .1 ±2.16 .5 ±1.2
BMI > 30 (n = 12) 12.0 ±2.51 6 .3 ±4.51 1 .1 ±2.36 .4 ±1.0
Normal GT (n = 27) 12.2 ±2.81 5 .4 ±5.31 1 ±2.46 .4 ±1.1
Impaired GT∗∗ and DM (n = 10) 11.6 ±2.61 5 .9 ±3.51 1 .4 ±1.36 .7 ±1.2
∗∗GT: glucose tolerance.
∗P<. 001 between control and groups..
ghrelin is correlated with HOMA in the patient group in-
dicating that this relation is independent from insulin resis-
tance and BMI, in keeping with the previous studies [13].
Yamamoto et al [17] have reported that adiponectin predicts
future insulin resistance in a two-year followup study. Hy-
poadiponectinemia, therefore, might well be an early predic-
tor of overt diabetes and overall or central obesity that might
emerge in patients with NAFLD in the future.
Hypoadiponectinemia has been found related with
necro-inﬂammatory activity [13]a n dﬁ b r o s i s[ 14]. Addi-
tionally,adiponectinhasanti-inﬂammatorypropertiesinthe
liver and its deﬁciency accounts for high aminotransferase
values and disease progression. A direct antiﬁbrotic eﬀect
of adiponectin has also been shown on the basis of expres-
sion of adiponectin gene in hepatic stellate cells [18]. Neither
serum adipokine including adiponectin nor ghrelin, how-
ever, is found associated with the histopathological sever-
ity in the present study. This ﬁnding does not lend sup-
porttopreviouslyreportedrelationshipbetweenadiponectin
levels and necro-inﬂammatory activity [13]. One explana-
tion of this controversy might be the ﬂuctuating pattern of
serum adipokine and ghrelin levels over time depending on
the metabolic milieu. Additionally, hepatic mRNA expres-
sion of adiponectin receptors (AdipoRII) in NASH inversely
correlated with the histological grade of ﬁbrosis but not with
serum and hepatic adiponectin [19]. Hence, the necroin-
ﬂammatory or ﬁbrogenic action of adiponectin seems to be
mostly depending on its intrahepatic production, ensuing in
autocrine or paracrine actions, in a cytokine-like manner.
Futurestudiesarewarrantedtoelicittherelativeinvolvement
of circulating versus locally produced adiponectin in the reg-
ulation of liver response to injury.
In conclusion, there is a signiﬁcant relation between
NASH and serum adipokine and ghrelin values irrespec-
tive of BMI and status of glucose metabolism. It seems that
this relationship is, at least partly, independent from in-
sulin resistance. Additionally, serum adipokine and ghrelin
that have been ascribed to have role in the pathogenesis of
NASH do not have any association with histopathological
severityofthedisease.Thisﬁndingindicatesthatfuturestud-
iesincorporatingtissuemeasuresoftheadipokinesandghre-
lin are required to elucidate the precise role of adipokines
upon histopathological severity in NASH.
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